Clinical Trial Update: Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002) [Phase 1]

View source ↗

Summary

Phase 1 single-dose escalation study of IDX184 (MK-2355-002) in healthy volunteers to assess safety and pharmacokinetics for Hepatitis C therapies; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IDX184 (IDX184)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED